There are an estimated 9 million Americans suffering from osteoarthritis of the knee, one of the leading causes of disability in the US. As noted by the FDA
The study met its primary endpoint of reducing monthly mean migraine days compared with placebo. The data were presented at the 17th Congress of the International Headache Society
The Chinese patent, along with several U.S. patents, cover a novel radiopharmaceutical molecule, which can be used for targeting dead and dying cells associated with cancer, inflammation, and
SanBio developed SB623 to promote regenerative processes in the central nervous system and provide therapeutic options for chronic stroke and other debilitating neurological disorders. United States Patent No.
The study showed the investigational cancer immunotherapy MPDL3280A (anti-PDL1) doubled the likelihood of survival (overall survival [OS]; HR=0.47) in people whose cancer expressed the highest levels of PD-L1
The company’s latest report* states that while this growth will be primarily driven by the potential introduction of four late-stage pipeline agents, consisting of reformulations of existing therapies
The Company’s legal counsel, Ferrere Abogados of Montevideo, Uruguay, represented the Company throughout the licensing process. The Company’s license is provisional and subject to the Company submitting additional
Under the agreement, Catalent will provide all cell line engineering, process development and clinical Good Manufacturing Practices (cGMP) biomanufacturing activities necessary for the rapid development of a high
The summary will be presented today at 10:15 a.m. EDT at the 4th Joint International Spinal Cord Society (ISCoS) and American Spinal Injury Association (ASIA) meeting being held
Moreover, stroke recovery was improved 2-fold in patients receiving THR-18, as judged by clinical outcome measures, 30 days following stroke. THR-18 is a novel drug-candidate designed to neutralize
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.